iPSC-Derived MSCs that Are Genetically Engineered for Systemic Bone Augmentation
Final rept. 15 Jul 2011-14 Jul 2013
LOMA LINDA UNIV CA
Pagination or Media Count:
Mesenchymal stem cells MSCs differentiated from Induced pluripotent stem cells iPSCs have a potential application in clinic to treat osteoporosis and other skeletal diseases. Further engineering MSCs with homing factors like CXCR4 and osteogenic factors like shNoggin or FGF2 may increase the therapeutic effects. Toward these goals, we have generated iPSCs using lentiviral vectors from blood cells and integration-free iPSCs using episomal vectors. The generated iPSCs are pluripotent, as evident by expression of pluripotency markers and formation of teratoma. After differentiation of iPSCs into MSCs, the cells express MSC markers and can form bone nodule in in vitro culture. To improve the safety of this therapy, we developed an alternative strategy for generating MSCs direct conversion of blood cells into MSCs rather than reprogramming blood cells into iPSCs followed by re-differentiation.
- Anatomy and Physiology
- Medicine and Medical Research